CA3079963A1 - Alk7 binding proteins and uses thereof - Google Patents

Alk7 binding proteins and uses thereof Download PDF

Info

Publication number
CA3079963A1
CA3079963A1 CA3079963A CA3079963A CA3079963A1 CA 3079963 A1 CA3079963 A1 CA 3079963A1 CA 3079963 A CA3079963 A CA 3079963A CA 3079963 A CA3079963 A CA 3079963A CA 3079963 A1 CA3079963 A1 CA 3079963A1
Authority
CA
Canada
Prior art keywords
seq
alk7
amino acid
sequence
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3079963A
Other languages
English (en)
French (fr)
Inventor
Ravindra Kumar
Roselyne CASTONGUAY
Dianne Sako
Jonathan Belk
Nathan J. Sharkey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Adimab LLC
Original Assignee
Acceleron Pharma Inc
Adimab LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc, Adimab LLC filed Critical Acceleron Pharma Inc
Publication of CA3079963A1 publication Critical patent/CA3079963A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3079963A 2017-10-25 2018-10-25 Alk7 binding proteins and uses thereof Pending CA3079963A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762577038P 2017-10-25 2017-10-25
US62/577,038 2017-10-25
PCT/US2018/057482 WO2019084249A1 (en) 2017-10-25 2018-10-25 ALK7 BINDING PROTEINS AND USES THEREOF

Publications (1)

Publication Number Publication Date
CA3079963A1 true CA3079963A1 (en) 2019-05-02

Family

ID=66246796

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3079963A Pending CA3079963A1 (en) 2017-10-25 2018-10-25 Alk7 binding proteins and uses thereof

Country Status (9)

Country Link
US (2) US11981738B2 (enExample)
EP (1) EP3700571A4 (enExample)
JP (2) JP7433222B2 (enExample)
KR (1) KR20200089666A (enExample)
CN (1) CN111836642A (enExample)
AU (1) AU2018354295B2 (enExample)
BR (1) BR112020007751A2 (enExample)
CA (1) CA3079963A1 (enExample)
WO (1) WO2019084249A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501547B2 (en) 2016-04-22 2019-12-10 Acceleron Pharma Inc. ALK7 binding proteins and uses thereof
CA3079963A1 (en) 2017-10-25 2019-05-02 Acceleron Pharma Inc. Alk7 binding proteins and uses thereof
AU2020282764A1 (en) * 2019-05-30 2021-12-02 Acceleron Pharma Inc. ALK7 binding proteins and uses thereof
JP7541709B2 (ja) * 2020-03-19 2024-08-29 株式会社CUBICStars タンパク質結合部位情報取得装置、タンパク質結合部位情報取得装置の作動方法及びプログラム

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
JP2001513652A (ja) 1997-06-06 2001-09-04 アサト アクチエンゲゼルシャフト アプライド サイエンス アンド テクノロジー 抗−ｇｐｉｉｂ／ｉｉｉａ組み換え抗体
AR055191A1 (es) 2005-10-12 2007-08-08 Morphosys Ag Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano
CA2896413A1 (en) 2008-12-05 2010-06-10 Abraxis Bioscience Llc Sparc binding peptides and uses thereof
AU2014368474A1 (en) 2013-12-19 2016-06-16 Arsanis Biosciences Gmbh Antibodies directed against the LukGH (LukAB) toxin of Staphylococcus aureus and antibody sequences
KR101644043B1 (ko) 2014-03-18 2016-08-01 한국과학기술원 Ｒｎａ에 특이적으로 결합하는 항체
US20170306027A1 (en) * 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
US10501547B2 (en) 2016-04-22 2019-12-10 Acceleron Pharma Inc. ALK7 binding proteins and uses thereof
CA3079963A1 (en) 2017-10-25 2019-05-02 Acceleron Pharma Inc. Alk7 binding proteins and uses thereof

Also Published As

Publication number Publication date
EP3700571A4 (en) 2021-07-28
JP2024023278A (ja) 2024-02-21
US11981738B2 (en) 2024-05-14
BR112020007751A2 (pt) 2020-10-20
AU2018354295A1 (en) 2020-04-30
JP7433222B2 (ja) 2024-02-19
CN111836642A (zh) 2020-10-27
KR20200089666A (ko) 2020-07-27
JP2021500895A (ja) 2021-01-14
US20200392233A1 (en) 2020-12-17
WO2019084249A1 (en) 2019-05-02
EP3700571A1 (en) 2020-09-02
AU2018354295B2 (en) 2025-08-14
US20240287196A1 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
US11708414B2 (en) ALK7 binding proteins and uses thereof
KR102084806B1 (ko) 인테그린 αvβ6에 대한 항체 및 암을 치료하기 위한 그의 용도
US20240287196A1 (en) ALK7 Binding Proteins and Uses Thereof
AU2020362827A1 (en) Anti-human Trop-2 antibody and application thereof
US12365736B2 (en) ALK7 binding proteins and uses thereof
RU2739208C2 (ru) Анти-pcsk9 антитело, его антигенсвязывающий фрагмент и их медицинское применение
CN116217731B (zh) Alk7结合蛋白及其用途
TW202517672A (zh) 抗ｃｄｈ１７抗體及其用途
HK40003020B (en) Alk7 binding proteins and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230929

EEER Examination request

Effective date: 20230929